Showing 2663 results
- Media Release /Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and…
- Media Release /The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration…
- Event /Novartis announced the company’s financial results for the third quarter of 2021.
- Event /Novartis announced the company’s financial results for the second quarter and first half of 2021.